Azamacrocyclic metal complexes as CXCR4 antagonists

Area of Science:

• Medicinal Chemistry
• Chemical Biology
• Pharmacology

Background:

• Chemokine receptor CXCR4, a GPCR, is crucial in diseases like HIV, cancer, and rheumatoid arthritis.
• Selective CXCR4 antagonists, such as AMD3100 and pyridyl macrocyclic zinc(II) complexes, are known inhibitors.

Purpose of the Study:

• To synthesize and evaluate novel metal complexes as CXCR4 antagonists.
• To explore structure-activity relationships by combining alkylamino and pyridyl macrocyclic features.

Main Methods:

• Synthesis of novel zinc(II) and copper(II) complexes.
• Assessment of anti-HIV activity.
• Evaluation of CXCR4-binding affinity.
• Measurement of inhibitory activity against CXCL12-induced Ca(2+) mobilization.

Main Results:

• Several new zinc(II) and copper(II) complexes exhibited potent anti-HIV activity.
• The synthesized compounds showed strong binding affinity to CXCR4.
• Significant inhibition of Ca(2+) mobilization by CXCL12 was observed.

Conclusions:

• The developed metal complexes are effective CXCR4 antagonists.
• These compounds hold potential for therapeutic development against CXCR4-related diseases.
• The findings support their use as chemical probes for studying CXCR4 biological activity.